Journal of Clinical Infectious Diseases & Practice
Open Access

HIV infection; Antiretroviral therapy; Virions; Virus infection

Introduction

HIV (Human Immunodeficiency Virus) remains a global health challenge, with millions of people affected worldwide. Understanding the dynamics of HIV infection and the effects of antiretroviral therapy (ART) is crucial for developing effective prevention and treatment strategies. One approach to studying HIV infection is through mathematical modeling, which can capture the complex interactions between the virus, the immune system, and the effects of therapy. In this article, we explore a stochastic HIV infection model that incorporates latent infection and the impact of antiretroviral therapy [1].

More and more mathematical models have been developed to reflect the dynamics mechanism of HIV virus. The classical HIV virus model is based on three-dimensional ordinary differential equations, which contains the target T-cells population, infected T-cells population, and virions. With the progress of HIV drug treatment, some researchers have investigated the effects of drug therapies on model behaviors [2]. The commonly used highly active antiretroviral therapy (HAART) is combined by reverse transcriptase inhibitors and protease inhibitors. Reverse transcriptase inhibitors can inhibit the activity of reverse transcriptase and prevent the formation of provirus during the virus infection; protease inhibitors can block the virus infection of new target T-cells. Unfortunately, the current drug treatment cannot eradicate the virus thoroughly. With the development of cell and molecular biology, it has been discovered that the existence of latent infection is a major obstacle to clear the virus [3].

In recent years, mathematical models with the inclusion of latent infected T-cells have been developed to investigate the model behaviors. However, all these models are deterministic model, and the effect of stochastic fluctuation factor is not considered. Actually, HIV transcription is an inherent random process and produces strong random fluctuations in the HIV gene products. Thus, by experimental data, it has been proved that these random factors seriously affect the evolution of HIV virus during the protease inhibitor therapy. Moreover, Weinberger et al. have demonstrated that stochastic fluctuation could play an important role in delaying HIV transactivation and contributing to latency [4]. Therefore, it is necessary to consider stochastic fluctuation in HIV virus model, which will be more appropriate to reflect the virus infection process.

Recently, the stochastic differential equation models of infectious diseases have been greatly developed, but the stochastic differential equation model of the virus dynamic model has just been developed. The classic three-dimensional stochastic model is studied in the earlier literatures, and then the virus stochastic model with target T-cell logistic growth and CTL immune response is also developed in the last two years. However, all these models did not consider the latent infection mechanism [5]. Conway and Coombs have formulated a stochastic model of latent infected T-cells, but they neither include the target T-cell logistic growth nor analyze the model dynamics theoretically. In this paper, we will formulate an HIV model with latent infection, healthy T-cell logistic growth, antiretroviral therapy, and random perturbations.

The stochastic HIV infection model

The stochastic HIV infection model takes into account the inherent randomness of events in HIV infection. Rather than assuming deterministic rates of infection and disease progression, the model incorporates probabilistic elements that better reflect the biological variability observed in real-world situations.

The model consists of several compartments representing different states of infection: susceptible individuals (S), individuals with acute infection, individuals with chronic infection, individuals with latent infection [6], and individuals receiving antiretroviral therapy (ART). Transitions between these compartments occur through various processes, including infection, viral replication, immune response, and therapy.

Latent infection

One of the distinguishing features of the stochastic HIV infection model is the inclusion of a latent infection stage. After initial infection, the virus may enter a latent state, where it remains dormant within host cells. This latent period can last for an extended duration, during which the virus is not actively replicating but can reactivate and lead to renewed viral production [7].

Latency plays a crucial role in HIV persistence and poses challenges for eradication. The stochastic model considers the probability of transitioning from the latent state to active infection, accounting for the interplay between viral factors, immune responses, and external factors such as stress or illness [8].

Antiretroviral therapy

Antiretroviral therapy (ART) has revolutionized HIV treatment by suppressing viral replication and restoring immune function. The stochastic model incorporates the effects of ART on viral load reduction, immune restoration, and the prevention of disease progression. ART can be initiated at different stages of infection, including during acute or chronic infection or even during the latent period.

The model takes into account the probability of treatment initiation, adherence to therapy, and the emergence of drug resistance. Additionally, it considers the potential for treatment interruption, reflecting real-world scenarios where individuals may discontinue therapy for various reasons [9].

Implications and insights

The stochastic HIV infection model with latent infection and antiretroviral therapy provides valuable insights into the dynamics of HIV infection and the effects of treatment. By incorporating stochastic elements, the model captures the inherent variability observed in realworld data, improving our understanding of the complex nature of HIV infection and disease progression.

This model can help evaluate the impact of different interventions, such as treatment strategies, prevention measures, and the timing of therapy initiation [10]. It allows researchers to explore the potential benefits and limitations of various approaches in controlling the spread of HIV and reducing disease burden.

Furthermore, the model can aid in predicting long-term outcomes and assessing the potential for viral rebound after treatment interruption. It can inform decision-making processes related to treatment guidelines, resource allocation, and public health policies.

Conclusion

The stochastic HIV infection model with latent infection and antiretroviral therapy offers a powerful tool for understanding the dynamics of HIV infection and the effects of treatment. By incorporating stochastic elements, the model captures the inherent variability and uncertainty associated with HIV infection, providing insights into disease progression, treatment outcomes, and control strategies.

Continued research and refinement of such models will contribute to our understanding of HIV pathogenesis and the development of more effective interventions. Ultimately, the goal is to improve the quality of life for people living with HIV, reduce transmission rates, and move closer to a world free of HIV/AIDS.

1. Klastersky J, Aoun M (2004) Opportunistic infections in patients with cancer. Ann Oncol 15: 329–335.

Indexed at, Google Scholar, Crossref

2. Klastersky J (1998) Les complications infectiousness du cancer bronchique. Rev Mal Respir 15: 451–459.

Indexed at, Google Scholar                    

3. Duque JL, Ramos G, Castrodeza J (1997) Early complications in surgical treatment of lung cancer: a prospective multicenter study. Ann Thorac Surg 63: 944–950.

Indexed at, Google Scholar, Crossref

4. Kearny DJ, Lee TH, Reilly JJ (1994) Assessment of operative risk in patients undergoing lung resection. Chest 105: 753–758.

Indexed at, Google Scholar, Crossref

5. Busch E, Verazin G, Antkowiak JG (1994) Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest 105: 760–766.

Indexed at, Google Scholar, Crossref

6. Deslauriers J, Ginsberg RJ, Piantadosi S (1994) Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest 106: 329–334.

Indexed at, Google Scholar, Crossref

7. Belda J, Cavalcanti M, Ferrer M (2000) Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 128:1571–1579.

Indexed at, Google Scholar, Crossref

8. Perlin E, Bang KM, Shah A (1990) The impact of pulmonary infections on the survival of lung cancer patients. Cancer 66: 593–596.

Indexed at, Google Scholar, Crossref

9. Ginsberg RJ, Hill LD, Eagan RT (1983) Modern 30-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 86: 654–658.

Indexed at, Google Scholar, Crossref

10. Schussler O, Alifano M, Dermine H (2006) Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 173: 1161–1169.

Indexed at, Google Scholar, Crossref